Company intelligence / Profile preview

siParadigm

Pine Brook, New Jersey, United Statessiparadigm.com ↗

Ownership: Private
Employees: ~315
Development stage: Commercial

Overview

siParadigm provides comprehensive molecular and genomic profiling for solid tumors and hematologic malignancies using advanced diagnostic technologies. Their test menu covers actionable aberrations including SNVs, InDels, CNVs, gene fusions, splice variants as well as tumor mutation burden and microsatellite instability. They offer both tissue-based and liquid biopsy testing with rapid turnaround times[1][4].

Therapeutic areas: Oncology
Modalities: Next Generation Sequencing (NGS)Flow CytometryImmunohistochemistry (IHC)Fluorescence In Situ Hybridization (FISH)Cytogenetics
Industry: Molecular Diagnostics

Partnerships

Acquired the clinical laboratory business of Cancer Genetics Inc. in July 2019[5].

Beyond the preview

Go deeper on siParadigm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on siParadigm.

Explore the full profile